Abstract
The aim of this guidance is to provide recommendations to clinicians and other interested parties on chronic urticaria in children. The Italian Society for Pediatrics (SIP), the Italian Society for Allergy and Immunology (SIAIP), the Italian Society for Pediatric dermatology (SIDerP) convened a multidisciplinary panel that prepared clinical guidelines for diagnosis and management of chronic urticaria in childhood. Key questions on epidemiology, natural history, diagnosis, and management were developed. The literature was systematically searched and evaluated, recommendations were rated and algorithms for diagnosis and treatment were developed. The recommendations focus on identification of diseases and comorbidities, strategies to recognize triggering factors, improvement of treatment by individualized care.
Highlights
Chronic urticaria (CU) is characterized by recurrent migrating skin lesions, called wheals or hives, angioedema (AE) or both lasting over 6 weeks
Search strategy aimed at gathering studies, published from June 1, 2009 that is the last year included in the previous SIAIP/Society for Pediatrics (SIP)/ SIDerP guideline on CU [12], to January 1, 2018 concerning prevalence, incidence, aetiology, diagnosis, therapy, prognosis and psychological issues of CU in children
Few data exist on epidemiology of urticaria in children, it is reasonable to think that prevalence and incidence of CU in developmental age are both below 1% (Level of evidence IV)
Summary
Chronic urticaria (CU) is characterized by recurrent migrating skin lesions, called wheals or hives, angioedema (AE) or both lasting over 6 weeks. In a Turkish non-comparative study, performed on 222 children with CU, 32,8% of patients were tested positive to C13-UBT but only in one case a complete remission of cutaneous symptoms after eradicating therapy was observed [56]. Other studies reported significantly higher levels of BAT in children with CSU compared to healthy controls [106].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
